Shared care follow-up for low-risk thyroid cancer patients using a digital reminder system
Shared Care Thyroid Cancer Follow-up Utilizing Thyroid Cancer Assessment Reminder System (TCARS) Study - A Pilot Study.
This study is testing a new digital reminder system to see if it helps low-risk thyroid cancer patients get better follow-up care by connecting their primary care doctors with specialists.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nova Scotia Health Authority Academic / other |
| Locations | 1 site (Halifax, Nova Scotia) |
| Trial ID | NCT05510934 on ClinicalTrials.gov |
What this trial studies
This pilot study evaluates the feasibility of a shared-care model for patients with low-risk differentiated thyroid cancer (DTC) by integrating primary care practitioners (PCPs) and specialists through a digital health-based thyroid cancer assessment reminder system (TCARS). The study will randomly assign 60 adult patients to either a shared-care group or a control group receiving standard specialist follow-up. The aim is to improve patient management and expedite referrals for any concerns regarding cancer recurrence. The study will assess the effectiveness of this model in enhancing follow-up care and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with low-risk differentiated thyroid cancer who have no evidence of cancer recurrence and are comfortable using a mobile application.
Not a fit: Patients without a consented primary care practitioner or those who do not have access to the internet may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve follow-up care and early detection of recurrence for low-risk thyroid cancer patients.
How similar studies have performed: While shared-care models have been explored in other contexts, this specific approach utilizing a digital reminder system is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Adult (\>18 years old) consenting patients being followed at the Halifax Interdisciplinary Thyroid Oncology Clinic (ITOC) meeting the following criteria: * AJCC stage 1 DTC with no radiological or biochemical evidence of thyroid cancer with undetectable high sensitivity serum thyroglobulin (hsTG \<0.06 mcg/L\*); * Anti-thyroglobulin antibody (anti-TG AB \<20 IU/ml\*); * Thyroid ultrasound scan \[USS\] negative for regional recurrence at least 24 months after most recent treatment; * AJCC stage 2 DTC with no radiological or biochemical evidence of cancer (undetectable hsTG and anti-TG AB and negative thyroid USS) at least 48 months after most recent treatment * Patient is comfortable with using the mobile or Medable application and has access to internet. Exclusion Criteria: Patient does not have a consented PCP.
Where this trial is running
Halifax, Nova Scotia
- Nova Scotia Health — Halifax, Nova Scotia, Canada (Recruiting)
Study contacts
- Principal investigator: Syed A. Imran, Dr. — Nova Scotia Health
- Study coordinator: Syed A. Imran, Dr.
- Email: Ali.Imran@nshealth.ca
- Phone: 902-473-2952
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.